GERN (37) NVCT (43) IRWD (69) CRMD (62) ⌘ Pro Terminal →

Zevra Therapeutics Inc. (ZVRA) — RQD Stock Rating Cockpit

$10.36 +0.49% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.35

Zevra Therapeutics Inc. (ZVRA) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $615.2M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.35 (-0.10%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (40/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.1% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ZVRA)Realized 20D OHLCV Swing Band: ±10.1%

Deterministic 5-Pillar Attribution (40/100 Composite)

🔍 WHY ZVRA SCORES 40/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+9/20 pts (23% of score)

FRED Regime × Technicals: 33% of 52W Range • RSI-14 at 45.7 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$11.39-12.7% Next Q

Q2 (-2Q)

Grade D$9.94-1.3% Next Q

Q3 (-1Q)

Grade D$9.81+5.6% Next Q

Current

Grade D-$10.36-7.4% Hist 90D α

Trajectory: D (48) → D- (40)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ZVRA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ZVRA currently carries a cautious 40/100 (D-) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.18) and Max Pain ($10.88) forces dealer call-delta covering toward $15.79.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZVRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ZVRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 40%NO 60%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

45.730 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

4 / 99-Pt Accounting

52-WEEK LASER RANGE33% OF RANGE

L: $8$10.36H: $15

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 4 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on ZVRA

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (20)

-32.3% ROIC with 42.0% gross margin and -0.40% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 4/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

14/40 institutional & smart-money positioning score with 9/20 macro alignment.

Bull Case: Why Buyers Like ZVRA

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZVRA)

✓Walkthrough of ZVRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ZVRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.87%📐 WEDGE COMPRESSION COIL

2026-10-30O $10.35H $10.49L $10.15C $10.36VOL 642.0K

RES: $11.02SUP: $9.48SMA50: $11.18SMA200: $10.75

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZVRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ZVRA Butterfly Map → + Track ZVRA →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-6.9%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZVRA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ZVRA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ZVRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZVRA)

Health Care Rank #635 of 1016 ⚔️ GERN vs ZVRA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ZVRA vs. GERN, NVCT, IRWD, CRMD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Zevra Therapeutics Inc. (ZVRA) ranks #635 by composite RQD confidence (40/100, grade D-) and #417 by equity capitalization ($615.2M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ZVRA at 40/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ZVRA ACTIVE Zevra Therapeutics Inc.	D-	40/100	7.4x	—	-32.3%	+0.49%	$615.2M	Benchmark Subject
GERN Geron Corporation	D-	37/100	—	—	-20.2%	-2.30%	$607.9M	/gern-vs-zvra →
NVCT Nuvectis Pharma Inc.	D-	43/100	—	—	-35.0%	+1.14%	$605.6M	/nvct-vs-zvra →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C+	69/100	24.9x	—	85.0%	+0.28%	$598.2M	/irwd-vs-zvra →
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-6.83%	$595.5M	/crmd-vs-zvra →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001434647

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Zevra Therapeutics Inc. (ZVRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of $83.2M, operating cash flow of -$1.6M, and free cash flow of -$2.4M (+96.5% YoY). On the balance sheet, ZVRA closed FY2025 with $284.7M in total assets against $61.9M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$83.2M	-$1.6M	-$2.4M	$284.7M	$61.9M
FY2024 (FY)	2024-12-31	$0	-$105.5M	-$69.7M	-$69.7M	$178.1M	$59.5M
FY2023 (FY)	2023-12-31	$0	-$46.0M	-$33.5M	-$33.5M	—	—

3. ZVRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZVRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Zevra Therapeutics Inc. (NASDAQ: ZVRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $10.36 (+0.49% 1D, market cap $615.2M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ZVRA ranks #635 in composite RQD confidence.

How does ZVRA compare to GERN and NVCT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ZVRA carries a Roarable D- (40/100 RQD), trailing P/E of 7.4x, gross margin of —, and ROIC of -32.3%. By comparison, GERN (Geron Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.2%, cap $607.9M) and NVCT (Nuvectis Pharma Inc.) posts a D- grade (43/100 RQD, P/E N/A, ROIC -35.0%, cap $605.6M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZVRA?

Per ZVRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001434647), Zevra Therapeutics Inc. generated $0 in revenue, $83.2M in net income, and -$2.4M in free cash flow against $284.7M in total assets and $61.9M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZVRA trading relative to its 50-day, 200-day, and 52-week technical levels?

ZVRA last traded at $10.36 (+0.49% on volume of 507,890 shares), positioning the stock -7.33% below its 50-day simple moving average ($11.18) and -3.63% below its 200-day simple moving average ($10.75). Across its 52-week range of $8.01 to $15.04, ZVRA sits at the 33.4% percentile with a 14-day RSI of 45.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($9.31 to $11.41).

ZVRA Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell ZVRA stock right now?

Zevra Therapeutics Inc. (ZVRA) currently earns a Roarable Rating of D- (Sell — SELL) with 40/100 RQD Confidence. Stretched risk/reward at 7x P/E (-32% return on capital) under elevated 10-year interest-rate pressure.

What is ZVRA's 12-month price target and RQD AI Jury consensus?

ZVRA's 12-month base price target is $9.52 (range $7.43 to $15.79), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: ZVRA RQD Cockpit ZVRA 12M Forecast ZVRA Earnings & Move ZVRA Dividends & DRIP ZVRA Insiders & 13F ZVRA Whale Options ZVRA Profit Sankey ZVRA News & Why